Products Categories
| CAS No.: | 183319-69-9 |
|---|---|
| Name: | Erlotinib hydrochloride |
| Molecular Structure: | |
|
|
|
| Formula: | C22H24ClN3O4 |
| Molecular Weight: | 429.903 |
| Synonyms: | 4-Quinazolinamine,N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride (9CI);6,7-Bis(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline hydrochloride;CP358774;4-Quinazolinamine,N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, hydrochloride (1:1);OSI 774;Tarceva;[6,7-Bis(2-methoxyethoxy)quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride;Erlotinib HCl;Erlotinib hydrochloride and Intermediate; |
| EINECS: | 620-491-0 |
| Melting Point: | 223-225 °C |
| Boiling Point: | 553.6 °C at 760 mmHg |
| Flash Point: | 288.6 °C |
| Appearance: | White or off-white powder |
| Safety: | 24/25 |
| PSA: | 74.73000 |
| LogP: | 4.28010 |
- 483366-12-7(2S,4R)-1-Boc-2-cyano-4-hydroxypyrrolidine
- 361456-36-2METHYL (R)-(+)-ISOCYANATO-3-PHENYLPROPI&
- 5156-58-1N-(1-Benzyl-4-pipperidinyl)-N-phenylpropanamide HCl
- 81281-59-67-Benzylideneaminotheophylline
- 50288-62-5threo-Phenyl-2-piperidyl acetamide
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 47087-37-6Z-D-Glu-OMe
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 211914-50-0N-[[2-[[[4-(Aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-(2-pyridinyl)-beta-alanine ethyl ester hydrochloride
- 240444-70-62,3,5,6-Tetrafluor-4-(methoxymethyl)benzyl-2,2-dimethyl-3-(prop-1-en-1-yl)cyclopropancarboxylat
- 183321-74-6
erlotinib
- 183319-69-9
erlotinib hydrochloride
| Conditions | Yield |
|---|---|
| With hydrogenchloride In isopropyl alcohol at 0℃; for 1h; Product distribution / selectivity; Inert atmosphere; | 100% |
| With hydrogenchloride In ethanol; water at 72℃; for 0.333333h; Solvent; Temperature; | 99% |
| With hydrogenchloride In water; acetone at 10℃; for 2.5h; Solvent; Temperature; | 98.7% |
- 1312937-41-9
6,7-bis(2-methoxyethoxy)-4-methoxyquinazoline
- 183319-69-9
erlotinib hydrochloride
| Conditions | Yield |
|---|---|
| Stage #1: hydrochloric salt of m-aminophenylacetylene With sec.-butyllithium In tetrahydrofuran; cyclohexane at 0℃; for 0.5h; Inert atmosphere; Stage #2: 6,7-bis(2-methoxyethoxy)-4-methoxyquinazoline In tetrahydrofuran; cyclohexane at 20℃; for 15h; Stage #3: With hydrogenchloride In tetrahydrofuran; cyclohexane; water at 20℃; for 1h; Product distribution / selectivity; | 100% |
| Stage #1: hydrochloric salt of m-aminophenylacetylene With sec.-butyllithium In tetrahydrofuran; cyclohexane at 0℃; Inert atmosphere; Stage #2: 6,7-bis(2-methoxyethoxy)-4-methoxyquinazoline In tetrahydrofuran; cyclohexane at 20℃; Stage #3: With hydrogenchloride In tetrahydrofuran; cyclohexane; water at 20℃; | 100% |
- 54060-30-9
3-acetylenephenylamine
- 183322-18-1
4-chloro-6,7-bis(2-methoxyethoxy)quinazoline
- 183319-69-9
erlotinib hydrochloride
| Conditions | Yield |
|---|---|
| In isopropyl alcohol for 18h; Heating; | 98% |
| In iso-propanol (IPA) for 0.5h; Product distribution / selectivity; Heating / reflux; | 97% |
| Stage #1: 3-acetylenephenylamine; 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline In N,N-dimethyl-formamide; acetonitrile at 90℃; for 7h; Darkness; Stage #2: With hydrogenchloride In water at 15 - 30℃; Temperature; Solvent; | 97.6% |
- 1312937-41-9
6,7-bis(2-methoxyethoxy)-4-methoxyquinazoline
- 54060-30-9
3-acetylenephenylamine
- 183319-69-9
erlotinib hydrochloride
| Conditions | Yield |
|---|---|
| Stage #1: 3-acetylenephenylamine With lithium diisopropyl amide In tetrahydrofuran; n-heptane; ethylbenzene at 0℃; for 0.5h; Inert atmosphere; Stage #2: 6,7-bis(2-methoxyethoxy)-4-methoxyquinazoline In tetrahydrofuran; n-heptane; ethylbenzene at 20℃; for 15h; Stage #3: With hydrogenchloride In tetrahydrofuran; n-heptane; ethylbenzene; water at 20℃; for 3h; Product distribution / selectivity; | 97% |
| Stage #1: 3-acetylenephenylamine With lithium diisopropyl amide In tetrahydrofuran; n-heptane; ethylbenzene at 0℃; Inert atmosphere; Stage #2: 6,7-bis(2-methoxyethoxy)-4-methoxyquinazoline In tetrahydrofuran; n-heptane; ethylbenzene at 20℃; for 15h; Stage #3: With hydrogenchloride In tetrahydrofuran; n-heptane; ethylbenzene; water at 20℃; Product distribution / selectivity; | 97% |
- 938185-06-9
N-(3-ethynylphenyl)-6,7-dihydroxy-4-quinazolinamine
- 4296-15-5
2-iodo-1-methoxyethane
- 183319-69-9
erlotinib hydrochloride
| Conditions | Yield |
|---|---|
| Stage #1: N-(3-ethynylphenyl)-6,7-dihydroxy-4-quinazolinamine; 2-iodo-1-methoxyethane With pyridine; tetrapropylammonium iodide In 1-methyl-pyrrolidin-2-one at 20℃; for 1h; Stage #2: With hydrogenchloride In water | 95.29% |
- 179688-29-0
6,7-bis(2-methoxyethoxy)-3,4-dihydroquinazolin-4-one
- 54060-30-9
3-acetylenephenylamine
- 183319-69-9
erlotinib hydrochloride
| Conditions | Yield |
|---|---|
| for 3h; Temperature; Reflux; Large scale; | 95.1% |
- 958669-57-3
4-(methylthio)-6,7-bis(2-methoxyethoxy)quinazoline
- 183319-69-9
erlotinib hydrochloride
| Conditions | Yield |
|---|---|
| With 3-ethynylaniline In isopropyl alcohol for 15h; Heating; | 90% |
- 766497-25-0
N-(3-trimethylsilyl-ethynyl)-6,7-bis(2-methoxyethoxy)-4-quinolyl-amine
- 183319-69-9
erlotinib hydrochloride
| Conditions | Yield |
|---|---|
| With hydrogenchloride In methanol at 20℃; for 1h; | 90% |
- 54060-30-9
3-acetylenephenylamine
- 183319-69-9
erlotinib hydrochloride
| Conditions | Yield |
|---|---|
| Stage #1: 6,7-dimethoxy quinazolin-4-one With triethylamine; trichlorophosphate In toluene at 70 - 80℃; for 3h; Stage #2: 3-acetylenephenylamine In toluene; acetonitrile at 20 - 80℃; for 2h; | 88% |
- 299912-59-7
3-butyn-2-ol, 4-[3-[[6,7-bis(2-methoxyethoxy)-4-quinazolinyl]amine]phenyl]-2-methyl, hydrochloride
- 183319-69-9
erlotinib hydrochloride
| Conditions | Yield |
|---|---|
| Stage #1: 3-butyn-2-ol, 4-[3-[[6,7-bis(2-methoxyethoxy)-4-quinazolinyl]amine]phenyl]-2-methyl, hydrochloride With sodium hydroxide In water; butan-1-ol pH=10 - 12; Inert atmosphere; Stage #2: With sodium hydroxide In butan-1-ol at 115 - 120℃; for 24h; Stage #3: With hydrogenchloride In water; butan-1-ol at 20 - 25℃; | 74% |
- 142217-69-4Entecavir
- 62613-82-5Oxiracetam
- 147127-20-6Tenofovir
- 134523-03-8Atorvastatin calcium
- 122111-03-9Gemcitabine hydrochloride
- 163222-33-1Ezetimibe
- 138112-76-2Agomelatine
- 654671-77-9Sitagliptin phosphate monohydrate
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
What can I do for you?
Get Best Price
Specification
1. Introduction of Erlotinib hydrochloride
Erlotinib hydrochloride, with the IUPAC Name of N-(4-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride, is one kind of white crystalline powder, odorless, little bitter taste. This product belongs to the Product Categories which include API; Molecular Targeted Antineoplastic; Heterocyclic Compounds; anti-neoplastic; Heterocycles; Intermediates & Fine Chemicals; Pharmaceuticals.
2. Properties of Erlotinib hydrochloride
Erlotinib hydrochloride has the following datas: (1)Flash Point: 288.6 °C; (2)Enthalpy of Vaporization: 83.44 kJ/mol; (3)Melting Point: 223-225°C; (4)Boiling Point: 553.6 °C at 760 mmHg; (5)Vapour Pressure: 2.69E-12 mmHg at 25°C.
3. Use of Erlotinib hydrochloride
Erlotinib hydrochloride (CAS NO.183319-69-9) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.